AbbVie Inc.
$514.13B- Market cap
- $454.36B
- Debt
- +$65.00B
- Cash
- −$5.23B
Capital structure 87% equity / 13% debt · EV / Revenue 8.41x · EV proxy / EBITDA proxy 22.15x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $454.36B · View financials
Snapshot Sep 11, 2026, 4:00 PM ET
FY 2026 ·
Decision snapshot: ABBV stock price at premium vs PG $257.12 current versus $51.79 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PG's multiple
Implied fair value · at ABBV's multiple
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 87% equity / 13% debt · EV / Revenue 8.41x · EV proxy / EBITDA proxy 22.15x
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 91% equity / 9% debt
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AbbVie Inc. · implied price per share
Bear
$87.89
Base
$110.94
Bull
$142.98
The Procter & Gamble Company · implied price per share
Bear
$81.64
Base
$98.63
Bull
$122.06
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
ABBV vs PFE
Johnson & Johnson
ABBV vs JNJ
Merck & Co., Inc.
ABBV vs MRK
Eli Lilly and Company
ABBV vs LLY
Amgen Inc.
ABBV vs AMGN
Gilead Sciences, Inc.
ABBV vs GILD
COLGATE PALMOLIVE CO
ABBV vs CL
KIMBERLY CLARK CORP
ABBV vs KMB
CHURCH & DWIGHT CO INC /DE/
ABBV vs CHD
CLOROX CO /DE/
ABBV vs CLX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABBV can sustain its premium multiples despite leverage and weaker net margin conversion, then avoid making a relative-value purchase versus PG because the current price embeds a valuation far above both PG and DCF estimates.
ABBV trades at a very large premium to PG across valuation metrics, with a P/E of 110.6x versus 23.3x and EV/EBITDA of 25.3x versus 17.1x. The model-implied price of $54.90 versus the current price of $261.11 implies -79.0% downside, and the stock is sitting above the top of PG-implied range but within its historical band.
Supporting Metrics